- Home
- DMO vs KZIA Comparison
DMO vs KZIA Comparison
Compare DMO & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DMO | KZIA |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.3M | 100.8M |
| IPO Year | 2009 | 2002 |
Fundamental Metrics
Financial Performance| Metric | DMO | KZIA |
|---|---|---|
| Price | $11.15 | $9.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 44.3K | ★ 139.4K |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.42 | $2.86 |
| 52 Week High | $12.11 | $17.40 |
Technical Indicators
Market Signals| Indicator | DMO | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 60.73 | 63.48 |
| Support Level | $11.07 | $5.64 |
| Resistance Level | $11.42 | $10.49 |
| Average True Range (ATR) | 0.18 | 0.84 |
| MACD | 0.06 | 0.17 |
| Stochastic Oscillator | 89.04 | 72.26 |
Price Performance
Historical ComparisonAbout DMO Western Asset Mortgage Opportunity Fund Inc.
Western Asset Mortgage Defined Opportunity Fund Inc is a non-diversified, limited-term, closed-end management investment company. The fund's primary investment objective is to provide current income. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing in a diverse portfolio of mortgage-backed securities, consisting of non-agency residential mortgage-backed securities and commercial mortgage-backed securities.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.